SCHEDULE 13D/A

Trevi Therapeutics Inc

Common Stock, $0.001 par value per share · CUSIP: 89532M101

Event date: 2025-08-07

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• New Enterprise Associates 16, L.P.Reported CIK 0001694560

  Shares: 15,074,080.00 · Class: 11.6%

• NEA Partners 16, L.P.Reported CIK 0001712881

  Shares: 15,074,080.00 · Class: 11.6%

• NEA 16 GP, LLCReported CIK 0001712882

  Shares: 15,074,080.00 · Class: 11.6%

• NEA 18 Venture Growth Equity, L.P.Reported CIK 0001880239

  Shares: 15,074,080.00 · Class: 11.6%

• NEA Partners 18 VGE, L.P.Reported CIK 0001898446

  Shares: 15,074,080.00 · Class: 11.6%

• NEA 18 VGE GP, LLCReported CIK 0001898598

  Shares: 15,074,080.00 · Class: 11.6%

• Forest BaskettReported CIK 0001277631

  Shares: 14,125,132.00 · Class: 10.9%

• Ali BehbahaniReported CIK 0001613867

  Shares: 15,074,080.00 · Class: 11.6%

• Carmen ChangReported CIK 0001746342

  Shares: 15,074,080.00 · Class: 11.6%

• Anthony A. Florence, Jr.Reported CIK 0001559827

  Shares: 15,074,080.00 · Class: 11.6%

• Mohamad H. MakhzoumiReported CIK 0001630226

  Shares: 15,074,080.00 · Class: 11.6%

• Scott D. SandellReported CIK 0001237289

  Shares: 15,074,080.00 · Class: 11.6%

• Paul WalkerReported CIK 0001553150

  Shares: 15,074,080.00 · Class: 11.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.